ADEMPAS IS THE FIRST MEDICINE APPROVED BY THE FDA TO TREAT ADULTS WITH:
- Pulmonary arterial hypertension (PAH) (WHO Group 1)The Adempas clinical studies included mostly patients with WHO functional class II–III symptoms. It is not known if Adempas is safe and effective in children.
- Chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) treated with surgery but who continue to have high pulmonary blood pressure (persistent) or it comes back after surgery (recurrent), or that cannot be treated with surgery (inoperable)
The Adempas clinical studies included mostly patients with WHO functional class II-III symptoms. It is not known if Adempas is safe and effective in children.
WHO=World Health Organization
THERE ARE NOW GENERIC VERSIONS OF ADEMPAS
What are generics?
Generic medications share identical active ingredient, dosage, strength, route of administration, and intended use as brand name medications.
How to maintain your current treatment routine
If you're concerned about a generic substitution occurring to your current Adempas treatment, talk to your doctor about "Dispense as Written."
What is "Dispense as Written"?
"Dispense as Written" is an option your doctor can take in all 50 states that helps to ensure the brand of medicine dispensed at the pharmacy is what was prescribed.
Check your pills to ensure you're receiving what was prescribed
Are you familiar with what your current brand of medicine looks like?
Pharmacies may fill your prescription with a generic without you realizing it. Always check your
pills before taking them. If you believe you've been dispensed a new brand of medicine without
you or your doctor being notified, reach out to customer support at the specialty pharmacy.
HOW FAR MIGHT ADEMPAS TAKE YOU?
Adempas can help increase your ability to walk farther and improve some of your symptoms. Patients with PAH and CTEPH taking Adempas were able to walk farther in a 6-minute walk distance (6MWD) test than patients taking a placebo (no Adempas) in the following studies:
Adempas and PAH
Change in 6MWD at the end of a 12-week study of 443 adults with PAH (WHO Group 1).
50% more patients who took Adempas improved their WHO functional class compared to patients who took a placebo (no Adempas).
21% of Adempas patients showed WHO functional class improvement vs 14% of placebo patients.
Adempas and CTEPH
Change in 6MWD at the end of a 16-week study of 261 adults with CTEPH (WHO Group 4).
50% as many patients who took Adempas improved their WHO functional class compared to patients who took a placebo (no Adempas).
33% of Adempas patients showed WHO functional class improvement vs 15% of placebo patients.
Adempas is the first member of a drug class called soluble guanylate cyclase (sGC) stimulators.
ADEMPAS HELPS KEEP BLOOD VESSELS OPEN
sGC is a chemical already found in your body that interacts with another chemical called nitric oxide (NO). Adempas stimulates sGC to carry out these interactions with NO, which are important in helping more blood flow through your lungs' blood vessels.